Table 1. Clinical characteristics in the TIV＋PPSV23 and the TIV＋Placebo groups.
| TIV＋PPSV23 ( n = 19) | TIV＋Placebo ( n = 21) | P Value | |
|---|---|---|---|
| Age, years | 66±8 | 67±8 | 0.663 |
| Male, (%) | 17 (89) | 18 (86) | 0.720 |
| Body mass index, kg/m 2 | 24.5±4.3 | 24.5±3.4 | 0.992 |
| Hypertension, (%) | 14 (74) | 17 (81) | 0.583 |
| Diabetes mellitus, (%) | 10 (53) | 11 (52) | 0.987 |
| Dyslipidemia, (%) | 18 (95) | 20 (95) | 0.942 |
| Current smoker, (%) | 3 (16) | 6 (29) | 0.334 |
| Family history of premature CAD, | 4 (21) | 6 (29) | 0.583 |
| Previous myocardial infarction, (%) | 8 (42) | 9 (43) | 0.962 |
| Prior PCI, (%) | 10 (53) | 13 (62) | 0.554 |
| Prior CABG, (%) | 4 (21) | 1 (5) | 0.120 |
| No. of diseased vessels | |||
| One, (%) | 5 (26) | 10 (48) | 0.165 |
| Two, (%) | 8 (42) | 8 (38) | 0.796 |
| Three, (%) | 6 (32) | 3 (14) | 0.191 |
| Ejection fraction, % | 64±9 | 64±10 | 0.791 |
| Medications | |||
| Aspirin, (%) | 16 (84) | 19 (90) | 0.550 |
| Thienopyridine, (%) | 7 (37) | 8 (38) | 0.935 |
| Calcium channel blockers, (%) | 11 (58) | 8 (38) | 0.210 |
| Beta-blockers, (%) | 7 (37) | 9 (43) | 0.698 |
| ACE inhibitors or ARB, (%) | 11 (58) | 16 (76) | 0.217 |
| Diuretics, (%) | 3 (16) | 7 (33) | 0.201 |
| Statins, (%) | 17 (89) | 17 (81) | 0.451 |
| Sulfonylurea, (%) | 1 (6) | 4 (19) | 0.188 |
| Thiazolidine, (%) | 1 (6) | 0 (0) | 0.287 |
| Biguanide, (%) | 1 (6) | 3 (14) | 0.342 |
| DPP-IV inhibitors, (%) | 4 (21) | 7 (33) | 0.385 |
| Insuline, (%) | 2 (11) | 0 (0) | 0.127 |
Values are mean±SD. INF = influenza; PC = pneumococcal; CAD = coronary artery disease; PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting; ACE = angiotensin-converting enzyme; ARB = angiotensin II type 1 receptor blockers; DPP = Dipeptidyl peptidase.